$191,000 in America, $44,000 in Japan: The Price of the World's Best-Selling Drug
Keytruda is one of the most important cancer drugs ever developed. It’s also one of the most profitable products in the world. In 2023 it was the best-selling drug on the planet, with about $25 billion in sales for Merck.
On February 8, 2024, Merck CEO Rob Davis sat before the Senate HELP Committee alongside the CEOs of Johnson & Johnson and Bristol Myers Squibb. The topic: why Americans pay so much more for the same medicines.
The numbers
- U.S. list price: about $191,000 per year (“That is close to being true, yes.”)
- Canada: about $112,000
- Japan: about $44,000 (“Generally, yes.”)
Then the key question: even at a quarter of the U.S. price, does Merck make a profit selling Keytruda in Japan?
“We do.”
Merck’s defense
Davis acknowledged that U.S. prices are higher than in many other countries, but argued Americans get something for it:
“We get access in the United States faster and more than anywhere in the world.”
In this view, the high-price U.S. market funds the research that produces the next generation of breakthroughs, and other countries’ lower prices are effectively subsidized by American patients and insurers.
The Capitalist Atlas take
Both things can be true at once:
- The U.S. pays more and gets faster, broader access to new drugs.
- Merck is still profitable at a quarter of the price in Japan.
The real question isn’t whether drug companies should make money. It’s who should pay for global innovation, and whether one country should carry most of the bill.
Go deeper
As an Amazon Associate, The Capitalist Atlas earns from qualifying purchases.
Footage: U.S. Senate HELP Committee, public record. This article is commentary and analysis, not medical or financial advice.
Source: U.S. Senate Committee on Health, Education, Labor and Pensions, hearing with pharmaceutical CEOs, Feb. 8, 2024 (public record)